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 x 
Smith-Magenis Syndrome (SMS) [OMIM, #182290] is a congenital anomaly and mental 
retardation (MCA/MR) syndrome associated with deletion of chromosome17p11.2 [1]. The clinical 
phenotype has been well described and includes minor craniofacial anomalies, self-injurious behaviors 
as well as sleep disturbances, speech delays, and obesity [1,2,3].  The incidence of SMS is estimated to 
be ~ 1:15,000 - 25,000 births [2,6]. Among SMS patients, ~90% are comprised of 17p11.2 deletions, 
while ~10% have RAI1 mutations [8].  All 17p11.2 deletions associated with SMS include RAI1 
deletion [10].   RAI1 is thought to function as a transcriptional factor although its cellular role is still 
unclear. 
 First, in order to better understand the role of RAI1 as a transcriptional factor and its relation to 
SMS, we confirmed that RAI1 regulates BDNF within an intronic region.  This sequence was further 
narrowed down by utilizing the luciferase reporter assay.  This test confirmed what was previously 
found using ChIP-chip assay and microarray analysis of Rai1+/- mice hypothalami.  Next, in order to 
evaluate the role of Bdnf, an ampakine drug was administered to the Rai1+/- mouse model.  A mouse 
model is a powerful tool for studying a specific gene.  Rai1+/- mice exhibit the SMS phenotypes of 
obesity, craniofacial abnormalities, reduced pain sensitivities, seizures and others.  Many physical, 
neurological, and behavioral tests were performed on the mice to see if any of the phenotypes can be 
rescued. Interestingly, twice-daily injections of ampakine CX1837 restored the pain sensitivities in 
Rai1+/- mice.  The hot plate data suggest that BDNF potentially has a role in regulating the SMS 
phenotype of decreased pain sensitivity.  In order to evaluate other genes that are altered as a result of 
the CX1837 ampakine drug, the whole brain's global gene expression was evaluated via microarray 
analysis.  Two potential pain-related genes were identified to be upregulated due to drug 
administration, which could account for the pain phenotypes observed.  One of the genes upregulated 
in treated mice was Osm, which is interesting because Osm is responsible for pain sensitivity. Further 
analysis is needed to confirm that an ampakine drug can potentially be used to treat SMS patients. 
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CHAPTER 1:  Background and Literature Review of Smith-Magenis 
Syndrome and RAI1 
 
Smith-Magenis Syndrome   
 
Smith-Magenis Syndrome (SMS) [OMIM, #182290] is a congenital anomaly and mental 
retardation (MCA/MR) syndrome associated with deletion of chromosome17p11.2 [1]. The 
clinical phenotype has been well described and includes minor craniofacial anomalies 
(brachycephaly, prominent forehead, broad nasal bridge), self-injurious behaviors (head - 
banging, wrist - biting) as well as sleep disturbance, speech delay, and obesity [1,2,3].  Most 
patients with SMS have a large and common deletion of ~4 Mb, but many other affected 
individuals have smaller deletions involving 17p11.2 [4,5]. The incidence of SMS is estimated to 
be ~ 1:15,000 - 25,000 births, which is thought to be an underestimate, due to either subtle 
clinical features seen early in life or the manifestation of similar phenotypes with other 
syndromes such as Down syndrome and Prader-Willi syndrome [2,6]. 
  
RAI1 and its role in SMS 
 
 The 17p11.2 region contains many repetitive elements, including low copy repeats and 
three highly conserved regions called SMS-REPS (proximal, middle, distal REPS) [7]. Within 
SMS patients, ~90% of the cases account for 17p11.2 deletions, while ~10% have RAI1 
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mutations [8]. Among the 90% of 17p11.2 deletion cases, 70% of patients have a common 
deletion of  ~3.5 Mb caused by homologous recombination between the distal and proximal 
REPs [9]. The other remaining 20% have atypical deletions (smaller or larger), with a minimum 
deletion of 700 kb in size[10,11]. All 17p11.2 deletions associated with SMS include RAI1 
deletion [10]. Although most of the SMS cases are de novo, one parental mosaicism case has 
been found [12,13].     
RAI1 (GeneBank AY172136, AJ271789; OMIM*607642) maps to the central portion of 
the SMS critical interval, adjacent to SREBF1[12]. The gene contains 6 exons, generating ~8.5 
Kb mRNA and 1906 amino acid proteins, with a molecular weight of ~203kD [12,14].  The 
protein contains two putative bipartite nuclear localization signals (NLSs), polyglutamine and 
polyserine tracts, and a PHD/zinc finger domain at the C-terminus [14,15]. RAI1 mRNA is 
ubiquitously expressed throughout the tissues, and relative to the other tissues, the heart and 
brain tissues have stronger expression by two- and threefold, respectively [14].  Northern blot 
showed similar expression levels of RAI1 in all the regions with the exception of the corpus 
callosum, where no expression was observed [14].  In mice, it has been shown that Rai1 is 
mainly expressed in neuronal brain structures during development and adult life and shares an 
84% homology with human RAI1 as well as similar expression patterns [14,16]. There are a few 
differences between human and mouse Rai1. For example, in humans, there are a total of 10 to 
18 glutamines, while in mice, this polyglutamine repeat is only 4 amino acids long [14].  Another 
difference is that the polyserine domain is present only in the human protein and not in that of 
the mouse [14].  Also, there is a human-specific carboxy-terminus [14].     
 Bioinformatic analyses suggest that RAI1 is likely to play a role as a transcriptional 
regulator, however, its cellular and developmental role is still unclear [15,17]. RAI1 shares more 
 3 
than a 50% similarity with TCF20, a transcriptional cofactor, and these two genes have a similar 
structure [18].  TCF20 is involved in growth and neurobehavioral regulation [15].   
 
SMS Clinical Overview   
 
 SMS phenotypes are clinically recognized via physical, developmental, neurological, and 
behavioral features [6].  These features of SMS become more pronounced and distinguishable 
with advancing age [19].  Also, significantly decreased fetal movement is noted in 50% of 
affected pregnancies [20].  Difficulty feeding is pronounced in early infancy, which ultimately 
leads to failure to thrive [20]. 
Physical features include craniofacial and skeletal anomalies such as high forehead, small 
nose with depressed nasal bridge, micrognathia, long philtrum with thin upper lip, broad square-
shaped face, and ear anomalies [3,6].  The most common physical findings include 
brachycephaly with flat midface, broad nasal bridge, brachydactyly, and short stature [2].  
Obesity is also commonly seen in teens and adults, along with broad chests [6].  Observed 
skeletal anomalies include brachydactyly, polydactyly, and fifth-finger clinodactyly, to name a 
few [1,3,21,22,23].     
The majority of SMS patients (96%) have delayed speech, with or without hearing loss 
[6].  Most SMS patients have mild-to-moderate mental retardation (IQ range= 20-78) [1].  
Individuals with SMS also have poor short-term memory but stronger long-term memory and 
perceptual closure [1]. 
 Behavioral phenotypes are one of the major concerns for SMS patients, as aggression, 
disobedience, distraction, and self-injurious behaviors are frequently observed [6].  It is also 
worth noting an observed decrease in sensitivity to pain in some cases, which may have play a 
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role in self-injurious behaviors. Self-injurious behaviors include head banging, skin picking, and 
wrist biting as well as onychotillomania (fingernail and toenail picking) and 
polyembolokoilamania (object insertions into bodily orifices) [2,6,24].  Some SMS patients are 
diagnosed with ADHD, OCD, autism, and hyperactivity [25].  Other neurological features 
include abnormal gait and balance problems.  Seizures are seen in 30% of patients [1,8].   
Sleep disturbance is one of the earliest diagnostic indicators of SMS, and has been 
reported in 75-100% of SMS cases [1,6,26].  The phenotypes include difficulties falling asleep, 
diminished REM sleep, fragmented and shortened sleep cycles with frequent nocturnal and 
early-morning waking, and many others [6].  Inverted circadian rhythms of melatonin are 
responsible for these abnormal sleep patterns [25,27].  All children with SMS who were tested 
displayed a phase shift in their circadian rhythm with irregular levels of melatonin during the 
day.  Melatonin reached peak levels at 12 PM ± 1, compared to a normal peak time of 3:30 ± 
1:30AM [25].  
 
Mouse model for SMS   
 
Mouse models are particularly useful in uncovering the functions of genes and studying 
human diseases.  The human chomosome 17p11.2 is highly conserved and syntenic to the mouse 
chromosome 11, which makes it feasible to establish a mouse model for SMS [4].  Rai1+/- 
(Heterozygous Rai1-mice) were created by insertion of an Escherichia coli lacZ coding sequence 
and a neoR expression cassette into Rai1 exon 2 while deleting 3910 bp nucleotides [28].  This is 
a strong model for studying the function of Rai1 in vivo, as it results in a truncation of the Rai1 
protein, eliminating all the nuclear localization regions and the PHD domain [28].  Rai1+/- mice 
were viable and fertile and weighted slightly less than the wild-type littermates until 2 weeks of 
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age [28].  However, they become significantly obese by the age of 20 weeks [28].  In addition, 
18% of the Rai1 +/- mice exhibit craniofacial anomalies including hyperthelorism (broader 
distance between the eyes) and shorter and broader snouts [29].  These anomalies were found to 
be due to malformation of the craniofacial skeletal elements, as indicated by skeletal analysis 
[28].  
For Rai1-/- mice (Homozygous Rai1-mice), significant embryonic lethality and postnatal 
growth retardation are observed [28].  Overall, the mouse model successfully replicates 
phenotypes seen in human SMS patients.  
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Chapter 2:  Confirmation of RAI1 regulation of BDNF 
 
Introduction 
 
 Mutation or deletion of Retinoic acid induced 1 gene (RAI1) results in Smith-Magenis 
syndrome. However, its cellular and developmental role is still unclear and very little is known is 
about the gene.  Looking at TCF20, which shares more than a 50% similarity, RAI1 is likely a 
transcriptional factor [18]. Transcription factors can bind to nuclear DNA or other proteins, 
forming initiation complexes and starting transcription of other genes. Transcription factors can 
also repress transcription by blocking the enhancer binding regions. In an effort to uncover the 
function and role of RAI1, another student in our lab performed chromatin immunoprecipitation 
with microarray (ChIP-chip) (S.R. Williams, data not shown) to find if RAI1 binds to any 
chromatin fragments. The analysis narrowed the top 10 candidate genes to SNRPN, UBE3A, 
CLOCK, MEF2A, BMP5, TRPC3, BCHE, CREM, and BDNF. In addition, microarray analysis 
on Rai1+/- mice hypothalami [30], showed that there was alteration in Bdnf expression among 
many genes. Quantitative RT-PCR analysis of hypothalamic tissue confirmed that the Bdnf level 
was downregulated by 2.5 fold in Rai1+/- mice compared to WT controls (B.M. Burns, data not 
shown). Taking these data together, testing whether or not RAI1 regulates BDNF on a molecular 
level would be the appropriate next step.   
 7 
Brain-derived neurotrophic factor (BDNF) is a second member of the “neurotrophic” 
family of neurotrophic factors, which was first isolated in the pig brain [31].  The BDNF gene 
has four 5’ exons (exons I-IV) with distinct promoters, and one 3’ exon (exon V) that encodes 
the mature BDNF protein [32,33]. The total of eight distinct mRNAs are transcribed 
predominantly in brain with some found in the lung and heart [33]. BDNF is synthesized as a 
preprotein which is proteolytically cleaved to release the mature form comprising of 120 carboxy 
terminal amino acids [33]. The highest levels of mRNA and constitutive BDNF protein are found 
within the hippocampus [34]. The BDNF protein is found to have a 50% amino acid identity 
with nerve growth factor (NGF) [35]. BDNF has been shown to support the development, 
survival, and differentiation of neurons but it is widely distributed in the central nervous system 
[36,37]. Altered expression of BDNF has been identified in depression, schizophrenia, and 
obsessive-compulsive disorder [36,38,39,40,41]. Further, haploinsufficiency of BDNF in humans 
is known to be associated with hyperphagia, obesity, and developmental problems [42].  
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Materials and Methods 
 
PCR amplification of the BDNF regulatory region. The BDNF intron 1 element identified by 
ChIP-chip  (Hg18, Chr11:27,680,656-27,681,712 Mb) was PCR amplified using Elongase 
(Invitrogen) following the standard protocol.  The Primer sequences for BDNF element are as 
follows (2692 bp): 
Forward: TGCCCGGTATGTACTCCTTC 
Reverse: CAATTATGCCAGAGGCCAAT 
 
Creation of plasmids. 
BDNF long
Luc 
: The amplified PCR product was Taq treated and cloned into StrataClone™ PCR 
Cloning vector using the standard protocol provide by the manufacture(Agilent Technologies, 
Santa Clara, CA), creating a BDNFStrata plasmid.  The insert was confirmed by standard Sanger 
sequencing.  The insert was removed by restriction digest with KpnI and SacI enzymes (New 
England Biolabs, Ipswich, MA).  The resulting product was run on a 2% agarose gel for 30min 
and purified using Qiagen (Germantown, MD) Qiaquick gene extraction kit according to the 
manufacturers’s standard protocols.  KpnI and SacI enzymes were then used to “prepare” the 
pGL3pro vector (Promega Corp, Madison, WI) and the isolated insert from BDNFStrata was 
directionally ligated into the pGL3pro vector to create BDNF longLuc using standard protocols 
provided by the manufacturer (Promega Corp, Madison, WI). 
 
BDNF Short
Luc : Using the BDNF longLuccreated above, an extra KpnI site within the  BDNF 
ShortLuc sequence was created by switching nucleotide A to T using a QuikChangeTM Site-
Directed Mutagenesis. After this, the nucleotide sequence was shortened to 792bp. This 
mutagenesis and cloning were done by Christine Bax in the Laboratory of Dr. Debbie Zies 
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(University of Mary Washington). The shorter form of the BDNF sequence is shown in Figure 1 
as underlined.  
 
Transfections.  (Protocol adapted from Stephen Williams’s Thesis, 2010) Human embryonic 
kidney (HEK293T) cells were maintained in 6-well dishes containing Dulbecco's modified 
Eagle's medium with 10% (v/v) FBS, 2 mM L-glutamine, and 100 µg/ml of 
penicillin/streptomycin (Invitrogen, Carlsbad, CA) at 37°C in a 5% CO2 167 incubator. The cells 
were counted using the trypan blue exclusion method to ensure >90% viability. Transfections 
with pUC19, psv! -Gal, BDNFLuc and RAI1Flag were performed using LipofectamineTM 2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.  Briefly, ~5 x 105 cells 
were plated in 2.0 ml of growth medium without antibiotics 24 hours prior to transfection.  A 
total of 4 ug of plasmid DNA, using pUC19 plasmid as “filler” DNA, were diluted in 250 ! l 
OptiMEM® Reduced Serum Medium (Invitrogen, Carlsbad, CA).  Similarly, 10 ! l of 
LipofectamineTM 2000 was diluted in 250 µl of OptiMEM® Reduced Serum Medium, mixed 
well, and incubated for 5 minutes.  After incubation, diluted plasmid DNA was mixed with 
diluted LipofectamineTM 2000 to a total volume of 500 µl and incubated for 20 minutes, then 
plasmid:Lipofectamine complexes were added to each well and mixed by rocking.  Cells were 
incubated at 37°C in a 5% CO2 incubator for 24 hours. 
 
Luciferase reporter assay.  (Protocol adapted from Stephen Williams’ Thesis, 2010) After 
plasmid DNA transfection and 24 h incubation, cells were washed with 2 mL DPBS (Invitrogen, 
Carlsbad, CA) and Tropix Glacto-LightTM (Applied Biosystems, Bedford, MA) for which the 
standard protocol was used.  Briefly, 250 ! l of lysis solution was added to each well of the six 
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well plate and the plate was scraped until all cells were detached.  Lysates were collected and 
centrifuged at 12,000RPM for 2min to pellet cell debris. Next, of the resulting supernatant 50 ! l 
was transferred to 4 wells of a 96 well white luminometer plate.  Two wells were treaded with 70 
! l diluted Galacton® substrate (1:100, Galacton:Reaction buffer dilutent) (Applied Biosystems, 
Bedford, MA) and incubated for 30min.  To the 2 wells that contained the diluted Galacton® 
substrate 100 ! l of Accelerator(-II) (Applied biosystems, Bedford, MA) was added.  To the 2 
wells that did not contain the diluted Galacton® substrate, 100 ! l of Steady-Glo® Luciferase 
substrate (Promega Corp, Madison, WI) was added.  Each well was read using the Wallac 1420 
VICTOR2™ Luminometer (PerkinElmer, Waltham, MA) on a maximum linear scale.   
 
Calculation of relative luciferase activity. (Protocol adapted from Stephen Williams’s Thesis, 
2010) Relative luciferase activity from each individual transfection was calculated by dividing 
the average number of light units read from the wells containing the Steady-Glo® Luciferase 
substrate by the average number of light units from the wells containing the Galacton® substrate 
and Accelerator(-II).  The equation (" Luc/" #-Gal=Relative luciferase activity) was used.  Wells 
containing pUC19, psv#-Gal, and BDNFLuc were used as baseline for luciferase activity.  Each 
experiment was performed independently at least three times.   
 
Statistical analysis. P-values were generated by averaging relative luciferase activity from each 
independent study and performing a two-tailed student’s t-test.  Standard deviations were 
generated using GraphPad.     
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Results 
 
Using a ChIP-Chip assay, a BDNF intron 1 region to which RAI1 putatively binds was 
identified. This BDNF region particularly maps to Chr11:27,680,656-27,681,712.  Taking this 
information, primers were designed to amplify this region (Fig. 1) and cloned into a StrataClone 
TA cloning vector, followed by subcloning into pGL3-Promoter vector (BDNF longLuc).  The 
pGL3-Promoter vector is useful as it contains a SV40 promoter upstream of the luciferase gene 
providing baseline luciferase activity.  HEK293T kidney cells were then utilized for transfection, 
as they have high transfection efficiency, and RAI1 is highly expressed in kidney cells.  The cells 
are co-transfected with RAI1a-GFP or RAI1c-GFP (Fig. 2) with BDNFlongLuc. as shown in 
Materials and Methods.  The relative luciferase activity was measured and compared between 1) 
RAI1Flag, pUC19, psv! -Gal, 2) RAI1Flag, BDNFlongLuc. , psv! -Gal, 3) BDNFlongLuc. , pUC19, 
psv! -Gal,  and 4) psv! -Gal only. Each time, the transfection was performed in duplicate, and 
luciferase activity was measured in duplicate as well. At least 3 runs were done for each isoform.  
The luciferase reporter assay was utilized to see if there was any alteration of expression, 
indicating whether RAI1 regulates by binding to this sequence.  As shown in Figure 3., there is 
~2 fold changes in relative light units when BDNFlongLuc. was co-transfected with RAI1 (isoform 
a). However, co-transfection of RAI1 (isoform c) with BDNFlongLuc. did not show any alterations 
in luciferase activity (Fig. 3). While RAI1 isoform a has 1906 amino acids, RAI1 isoform c only 
has 966 amino acids and lacks both a RAI1 bipartite nuclear localization signal and PHD domain, 
which are thought to be important for transportation of RAI1 into the nucleus for proper 
transcription to occur (Fig. 2).  Therefore, this result was not surprising.  A schematic diagram 
comparing RAI1a and RAI1c is shown in Fig. 2. Overall, the result shows that RAI1 binds to the 
cloned BDNF regulatory region, and regulates its transcriptional activity. The next question that 
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arises is whether it is possible to narrow down the binding sequence.  
Following this question, the shorter form of BDNF (BDNFshortLuc. ) was created by 
removing 1809 bp, thereby resulting in the 780 bp sequence, as shown in Materials and Methods.  
This form was utilized to potentially further narrow down the BDNF regulatory binding 
sequence to which RAI1 (isoform a) binds. Interestingly, the reporter system expression level 
retained a ~ 2 fold increase when the BDNFshort Luc. was co-transfected with RAI1a. This 
suggests that the RAI1 binding site/regulatory sequence is still present in the BDNFshortLuc.  
With this information together we have confirmed that RAI1 has a direct binding in the 
BDNF intronic region, and we have further narrowed down its sequence to Chr11:276,648,82 -
276,656,73.  Now, it is our goal to uncover the role BDNF plays in SMS phenotypes.  
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TGCCCGGTATGTACTCCTTCtgttctgcagcaaagaagttaaattattgatagtggaaattgcatggcggaggtaatactcg
caccccatcagcgagaagctccatttgatctcggcagaggcagggagatttcatgctagttcgccggggggagcggcagcgagagcagc
cctctccgcggtgaatgggaaagtgggtgggagtccacgagagggctccacggtgccttgacgtgcgctgtcatatgatacctccgctgcc
tcgaaatagacactctagtgcacgaattaccagaatcaaaattcagcgcatttaaaatgatacatcttttattagaagagttccgttccagggca
ttgcatgcttttgcagatgttttcacttccagccccagcaaacacacgtataagctaacccttttaataacgaaccagggcagccaagataaat
aaaaagtcttctgctttaaccagagtgggggtaggtgattcgagggtgggggcagaactggctcagttaatcctcccccgccctccaccccc
accactgcccgcagcaaaagagcaaatagcctttcgggttctcatttgcctgtagccaagacccttgaagagaacttatatggctagggtcca
gaggacattttcaattatccatttgatgaactctgtcaaccgtctacctgtgtttctgctttaaagctgaattttcttctcattagttcaaccaatttgtg
cagaccttaaaatttagaataaagaataagacagcagtaccgtacttaacttggagtccctggacctcctcggagcataaaaatcacctgggt
gagtgttaaaatgaaggtccctcctcctgaaattgtgatttagtaggggtggggcagggcccaggagttataattttaataaataccacaagca
attcgaatgcagacaatctgaagtcacactttgagaaacactctcttgggggtacaacactgggtatcagaggaatctcccaccaagcccac
acccaaattctgcaggcagctttctgtgtgtgtgcgtttttctgtaatctcaaaggggtttgacctaataattgcgaagactattgctgtaagaattt
ccctaaagactccaacattaattttgctaaagggaaagatttataaacagtttcctttcctggaccctcttgtggttaccaagaatgtgctgttgaa
ctgaatatataatattattacatactcagttcaatttacctaagggtttacagttagcaaaatgaattcactaacattagctattttagaacttctaaa
gactagtgacagaaattatttacccgttttataaaagaagaatccgatcctctgccaggaaataatttacccacgttcacacagtgaagtacca
gggacaagacttcagtgaactcaagaattcctgctagaaataaccctgcttccatctcccccaccccctaagtgaagctatctgttccttggaa
gtgttatcagaatgtgtgatcattcagagcgcctttgcaaattgttggactaaatagtcaaattattcaaatatatgcatattcttcgagtgtcacac
atttagctttgcacctctgtcaacttgacagagcacatgaccaatacaaactaccctacagcacagatggcagagtttattgtggaatatttaat
gtatgtgaaatacgcaggctaaccagaaagcaataaaggacagagggcatgaagctggataccgctaccccacagaccctctgcgttggt
tcccaggttgtaagatgaatgcaggcacaatttcttttagtagcacaatacaatttaaaaggctagtgttatacatttaaaaaaaatacttgtacta
cattataaaggactggaggaaccctactccaaactttaactttgttaacttcaaactgatgcttcacatttgcttgaaaatgagttctacc
ctcaggtttttaagctcaattgtaatttatttccttcctgaaaaaatacctggcaagttaatgccaggaatctaagctagcattctgaa
ggctgctcacttagaagttatggcaaatcttttttctgctaaattcacattggcacgtcagcatttctgctgaaggaaaaagtgttctca
tttcccagactctgattgggtgggtctatggccaatcttcttattcctactctcccttgacattatataaataaatgtgtgtatcttcgcttt
ccagtgtgtggtgcagttttactgaggaaaagacagaggagtcagaaatgtcagggatatttagaaagaaaagaagatcagatgc
caattcagataaccatgatgaatcacacctcttaacacttgtaagcatttccaaactttctgatttgtgattatagcattgccaatactg
tatgcgaccagcttaaaacatgtacttatttgccttaaaagtacatcttacattcaaaaacaatgaagccaagataaacaaaattgt
accagtgccttgcatggaattctaaatattattttttatttgcttaattcaggtagcatatagagataattttggaggtctaaaatcaaa
cattttacaaaattatttccctattgtgggcaaggatgatgctgagaatatagagcatgcatttctcttcttcttaaaaATTGGCC
TCTGGCATAATTG 
 
 
Figure 1. Amplified BDNF long sequence and short sequence with RAI1 binding site. 
Highlighted region shows sequence from ChIP-chip analysis (Chr11:27,680,656-27,681,712). 
Bold and underlined sequence is shows sequence of BDNF in BDNFshort Luc. 
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A.  
 
 
 
B.  
 
Source from Burns et al., 2010 
 
 
Figure 2.  Schematic diagram of RAI1a and RAIc structures.  A. Predicted gene structures of 
RAI1 isoforms are shown. RAI1a has 1906 amino acids, while RAI1c only has 966 amino acids 
which lacks nuclear localization and PHD domains. B. DAPI staining of nuclei transfected in 
HEK293 with RAI1a-GFP shows localization to the nucleus while RAI1c-GFP shows 
localization to cytoplasm. 
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Figure 3. BDNF expression is regulated by RAI1 isoform a. Luciferase activity of RAI1 co-
transfection with BDNFlongLuc. Negligible luciferase activity was detected from well containing 
! -gal only. n!3. *** p < 0.0001.  
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Figure 4. Narrowing down the BDNF region RAI1-a regulates.  Luciferase activity of RAI1 
co-transfection with BDNF longLuc. Negligible luciferase activity was detected from well 
containing ! -gal only. n!3. *** p < 0.0001.  
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Discussion 
 
Data presented here illustrate that one of the genes that RAI1 regulates is BDNF.  The 
luciferase data clearly show that that RAI1 (isoform a) is positively regulating gene expression 
via the BDNF intronic region illustrated in Fig. 3 by binding directly to or within the subunit.  
While there is a two fold increase in luciferase activity with cotransfection of RAI1a and 
BDNFLuc., there was no alteration of luciferase activity with RAI1c.  However, it is worthwhile to 
pay as much attention to co-transfection of RAI1c. By utilizing RAI1c, with its lack of NLS and 
PHD domain, it provides us with a confirmation that NLS and PHD are an essential part of 
RAI1.  These data also suggests that RAI1c is likely playing a role elsewhere in the cell.  Further 
investigation needs to be done on RAI1c.  
In addition, using the shorter form of the BDNF intronic sequence (BDNFshortLuc.) we 
were able to show that enhancement of transcription was maintained in the reporter assay.  Since 
there was not much difference between the activities of BDNFlongLuc. and BDNFshortLuc. , it is 
apparent that the binding region is still present in the short form.  Overall, the data successfully 
reveal two main conclusions: 1) RAI1 has a positive a role in regulating BDNF via the intronic 
region.  2) The region of BDNF to which RAI1 binds has been narrowed to ~800bp in BDNF 
intron 1.  
BDNF is known to function in development, survival, and growth of neurons [37,43]. 
With its highest expression of both mRNA and protein in the hippocampus, which is known to 
be the site of the long-term memory, BDNF is associated with learning and memory [44]. Many 
reports have also demonstrated decreased level of BDNF in certain neurological diseases [45]. 
Taking these facts together, it seems that the central role of BDNF is taking place in the brain. 
On the other hand, reduced expression of BDNF has been associated with obesity [42,46]. As 
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many of the phenotypes of SMS are not exclusive, the next asks will be to narrow down the role 
of BDNF in SMS phenotypes.   
Overall, this study provides a piece of the puzzle toward understanding RAI1 regulation 
of BDNF.  It would be wise to look at the other top candidate genes that were found in ChIP-chip 
analysis to see if any can be confirmed on a molecular level, which would reveal more about the 
cellular function of RAI1, and help us to discover more of the many roles of RAI1.  I believe that 
one day, most of the pieces to the puzzle will be found, and that we will be able to connect the 
pieces together and have a much greater understanding of the role of RAI1 than what we do now.  
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Chapter 3. Exploring the effect of ampakine drug treatment on Rai1+/- mice 
 
Introduction 
 
 The previous study suggested that RAI1 is likely regulating expression of BDNF.  Also, 
Bdnf expression is significantly lower in the Rai1+/- mice compared to WT mice. BDNF was 
first purified in a pig brain based on its survival promoting action on dorsal root ganglion [31].  
BDNF is known as an important regulator of synaptogenesis and synaptic plasticity mechanisms 
underlying learning and memory in the adult CNS.  Another important role for BDNF in 
adulthood appears to be as a central modulator of pain [47].  The perception of pain implicates 
the activation of peripheral (cutaneous, muscular, articular or visceral) nociceptors, the 
generation of a nerve signal and the transmission of this signal to the somatosensory cortex.  Rats 
subjected to the ligation of a spinal nerve (SNL) exhibited a hypersensitivity to thermal and 
mechanical stimuli that was reduced by intrathecal administration of BDNF [48].  Another study 
has shown that BDNF is required for the early postnatal survival of nociceptors [49].  
BDNF is also known to suppresses food intake [50].  Furthermore, it has been reported 
that BDNF regulates food intake and glucose homeostasis in genetically obese animal models 
[51]. In heterozygous Bdnf +/- mice, with its BDNF gene expression, hyperphagic behavior and 
dramatic obesity were reported [52]. 
Most cellular actions of BDNF’s are mediated by its high-affinity receptor, the 
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neurotrophic tyrosine kinase receptor type 2, or TRKB [53,54].  TrkB is abundant during 
development, but also widely distributed in the CNS of adult animals, suggesting a continuing 
role for BDNF in the adult nervous system [47].  Human patients with TRKB defects also exhibit 
hyperphagia and obesity along with impaired learning and memory [55]. 
The mouse Bdnf gene (GeneBank AY05907) contains eight 5’ noncoding exons and one 
3’ protein coding exons [56,57]. In mice, Bdnf mRNA is expressed throughout development and 
differentially in adult tissues. Similarly to the human model, Bdnf mRNA and protein expression 
is found throughout the brain with the highest expression in the neurons of hippocampus 
[58,59,60].  Neuronal Bdnf expression is affected by many stimuli such as GABAergic and 
glutamatergic neurotransmission and membrane depolarization through calcum-mediated 
pathways [61,62]. Gene expression is controlled by multiple activity-dependent and tissue-
specific promoters that produce a heterogeneous population of BDNF mRNA [56].   
Homozygous knockout Bdnf mice -/- lack these neurons [63]. Knockout of Bdnf-/- 
knockout mice are lethal and fail to survive past 3 weeks, while heterozygous Bdnf knockout (+/-
) mice exhibit various phenotypes, obesity being one of them [52]. 
There are numerous studies showing that ampakine drug treatment increases protein 
BDNF levels. Recent studies showed that elevation of BDNF expression can be achieved both in 
vitro and in vivo using ampakines [64,65,66].  Ampakines are a novel neurolpharmacological 
class of small molecules that trigger the AMPA-type of glutamate receptors and increase ligand-
gated current flow [67,68,69].  These compaounds were originally derived from aniracetam [69]. 
Also, repeated treatment with ampakines can increase the efficiency of long-term potentiation in 
the hippocampus and facilitate memory process [70,71,72].  The potential significance of 
ampakines arises from its ability to readily cross the blood-brain barrier, improve short term 
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memory, and facilitate olfactory learning with no evident side effects [73,74,75].  
Several studies have used ampakine to restore Bdnf levels in mouse models of diseases.  
In the Huntington disease knock-in mouse model, upregulation of BDNF with twice daily 
injections of ampakine showed rescue in synaptic plasticity and memory by means of 
normalizing the BDNF level [76].  This study suggested that ampakine treatment can be a 
potential strategy for chronic treatment of Huntington disease [76].  Also, another study showed 
that ampakine treatment improved Bdnf expression as well as respiratory function in a mouse 
model of Rett syndrome [77]. Furthermore, ampakines are under investigation as a potential drug 
treatment for Alzheimer’s disease, Parkinson’s disease, schizophrenia, ADHD and other 
disorders that involve mental disability and disturbances.  Based on this information, it seems 
that ampakines are a great candidate drug for increasing the expression of Bdnf to potentially 
provide a partial rescue of phenotypes seen in Rai+/- mice.  
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Materials and Methods 
 
Mouse models, breeding, and maintenance.  Mice evaluated in this study were C57Bl/6J 
Rai1+/- animals bred from stock received from Jackson Laboratories (stock #005981).  Due to 
poor in-house breeding of this line, the mice were outcrossed to FVB/N to improve the number 
of offspring obtained.  When the mice were being bred or in feeding studies, they were given 
access to a higher fat (9%) Lab Diet, 5P06 Prolab RMH 2000, and water.  An automatic 12-hour 
light/dark cycle was provided at all times along with constant temperature (21C) and humidity 
(40%).  The overall phenotype of these mice is muted in this mixed background, but the FVB/N 
x C57Bl/6J Rai1+/- animals are overweight and have craniofacial anomalies similar to the B6 
congenic strain originally evaluated.  
 
Genotyping.  Mice were genotyped by PCR analysis using template genomic DNA from mouse 
tails prepared as previously described (Girirajan et al., 2008).  Rai1+/- genotypes were 
confirmed using target allele and wild type primers as reported in B et al., 2005.  Reactions were 
held at 94C for 5 min followed by 42 cycles of denaturing at 94C, for 1min, annealing at 60C 
and an extension at 72C, for 1 min, followed by a final extension at 72C, for 7 minutes. 
Reactions were held at 4C until use.  
 
Ampakine drug preparation. CX1837 (Cortex Pharmacueticals) was dissolved at a 
concentration of 0.25 mg/ml in 2-hydroxypropyl-#-cyclodextrin (HPCD) powder, with equal 
weights of water and 0.9% injectable saline as a 1:1:1 mixture, or 33% HPCD in water/0.045% 
saline.  Once the HPCD powder was dissolved, the total volume was split in half.  Ampakine 
CX1837 was added to half of the volume, and the remaining half was used as a vehicle.  The 
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solution containing Ampakine CX1837 was then submerged in a sonicator heated to 37C and 
then frequently vortexed to aid solubilization.  The resulting solution is a clear viscous liquid 
stored at 4C.   
 
Ampakine injection.  Each mouse was weighed weekly and given 1 mg/kg of ampakine 
CX1837 twice daily (10:00 a.m. and 5:00 p.m.).  A vehicle solution was used at the volume of 
0.25mg/mL.  The solution was mixed well before use to get rid of any precipitation that had 
formed in storage.  The volume of drug administered was altered once a week to account for 
weight fluctuations in the mice.  The mice were anesthetized with isofluorane prior to 
intraperitoneal (IP) injection.  Each mouse received the dose in the same order every day.  The 
four treatment groups included wild type (WT vehicle treated, WT drug treated), Rai1+/- vehicle 
treated, and Rai1+/- drug treated. 
 
Physical assessment and simple reflexes: 
Sound orienting.  Brief and sharp noise was made to the right and left of the mouse's ear.  A 
turn in the direction of the noise source was noted. 
Pupil constriction/dilation.  A beam of light was shone in the direction of the mouse’s eye. 
Constriction when the light was shown and dilation when the light was removed were noted. 
Whisker response.  A small paint brush was used to lightly brush the whiskers of the mice and 
their response was observed.   
Eye blink.  The tip of a clean cotton swab was used to approach the eye and determine if the 
mouse blinked in response.  
Ear twitch. The tip of a clean cotton swab was used to touch the mouse's ears to see if the ear 
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twitches in response (both ears were tested).   
Postural reflex.  The mouse was placed in an empty cage that was tilted from side to side, and 
up and down, and the mouse’s ability to maintain an upright position was observed.  
Response to being picked up by tail. Mice were picked up by the base of their tail and held for 
10 seconds. The mouse was then lowered to the ground. Limb extension upon lowering to 
ground, as well as head raising were measured visually.  
Gaiting test.  Each of the mouse's feet was colored a different color (non-toxic material).  The 
mouse was then allowed to walk through a small tunnel on white paper. Stride, sway, and stance 
measurements (in cm) were made.  Stride was defined as the distance between two rear paw 
prints, and sway as the distance between paws from side to side, and stance as the diagonal 
distance between two front or back paws.  
Hot-plate test.  The mouse was placed on an analgesic hot plate set at 60C and the time (in sec) 
it took for the mouse to display a common response (jump, raise pay, paw lick or paw shake) was 
measured.  Unusual responses were also noted.  The maximum trial time was 30 sec.  
Tail flick test.  The mouse was restrained gently with its tail placed in the groove of the tail flick 
apparatus.  The 8V (6 amp) light automatically extinguished once the tail was removed. The 
maximum trial time was 10 sec.  
 
Behavioral test: 
Operant conditioning test.  For operant responding tests, eight standard mouse operant 
conditioning chambers that were sound- and light-attenuated (MED Associates, St. Albans, VT) 
were used.  Each operant conditioning chamber (18 x 18 x 18 cm) was equipped with a house 
light, two levers (left and right), and a recessed food pellet receptacle centered between the 
 25 
levers.  A hopper delivered food pellets into the receptacle.  Fan motors provided ventilation and 
masking noise for each chamber.  House lights were illuminated during sessions.  A computer 
with Logic ‘1’ interface (MED Associates) and MED-PC software (MED Associates) controlled 
schedule contingencies and maintained data.  A food pellet was released every time the right 
lever was pressed.  Mice were placed in the box and allowed to lever press for three 15 minute 
sessions throughout the course of the study.  For the final test, mice were food deprived 
overnight and then placed in the chamber for 1 hour.  Data was recorded as total number of lever 
presses. This testing was performed by Mary Tokarz.  
 
Growth assessment: 
Weight gain.  Mice were weighed on a weekly basis to assess growth and weight gain or loss 
due to drug administration.  
Feeding study.  Food was weighed daily for a 5 day period. Mice were placed in isolation cages 
with a predetermined amount of normal chow (5% fat) and an unlimited amount of water. Food 
was weighed every 24 hours.  
 
Gene expression studies: 
RNA isolation.  RNA was isolated using the Trizol reagent/chloroform method.  The quality of 
isolated RNA is assessed by using a 260/280 and 230/260 absorbency ratio and the concentration 
was obtained using Nanodrop.  
Real-time quantitative PCR.  cDNA synthesis was performed using 4-5 ug of RNA, Invitrogen 
Superscript 2 reverse transcriptase and random primers according to the manufacturer’s 
instructions.  An ABI TaqMan probe for mouse mRNA expression was used to detect expression 
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of Bdnf.  All samples were analyzed in triplicate in a 10 uL reaction on an ABI Prism 7500 Fast 
System with Gapdh as an endogenous control.  
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Results 
 
I. Initial study- First round 
The initial study was conducted with 6 mice; 3 females and 3 males. Of the 3 females, 2 
were Rai1+/-, receiving vehicle and drug respectively, and 1 was WT, receiving vehicle.  Of the 
3 males, 2 were Rai1+/- , with both receiving drug and vehicle, and 1 was WT, receiving 
vehicle.  The 3 female mice were born on the same day from the same mother, and the 3 male 
mice were born the week after.  The ages of the females and males when the treatment was 
started was 9 weeks and 8 weeks, respectively.  It is important to note that the mice used in the 
study were 50:50 mixed background progeny of C57Bl/6J and FVB/NJ, as pure Rai1+/- 
C57Bl/6J background mice have difficulty breeding and have reduced transmission of the mutant 
allele.  The phenotypes observed in these mice are generally milder than the pure C57Bl/6J and 
varied greatly among the mice, (i.e. some had more pronounced phenotypes than others) and the 
behavioral characteristics of the mixed background mice were very different, as they were 
jumpier and more active than the pure C57Bl/6J mice.    
Mice were evaluated for each test in the same order each time.  Also, the mice were 
anesthesized under isoflourine before each  treatment.  It took a few minutes after the treatment 
for them to fully wake up and get back to normal.  Therefore, all the tests describe below were 
performed a few hours after the drug treatment.  
 
Neurological testing 
Before any other tests were done, a general physical assessment was made and simple 
reflexes were tested.  A note was made of any abnormal behavior after treatment was given.  
This was ensure that the drug does not have any negative side effects or a sedative effect.  
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Further, this examination ensured the accuracy of the results of any other testing.  The mice were 
first tested for sound orientation, pupil constriction/dilation, whisker response, eye blink, ear 
twitch, postural reflex and response to being picked up by the tail.  Regardless of their genotypes 
and whether they received the vehicle or drug, the mice all showed normal responses to these 
tests.  The mice were able to turn in the appropriate direction when noise were made near their 
ears, and their ears twitched when touched with a cotton swab (data not shown).  They blinked 
when a cotton swab was held near their eyes, and proper constriction/dilation were observed 
when a light was shown/removed (data not shown).  When the cage was shaken up and down, as 
well as side-to-side, all mice were able to maintain their balance and remained upright (data not 
shown).  When they were being picked up by the base of the tail, all of them raised their heads 
and reached for the ground upon lowering, which is the normal response (data not shown). 
Gating was analyzed for each mouse.  As described in Materials and Method, stride, 
sway, and stance length were measured.  As shown in Fig. 5, there were no differences between 
the groups when they were measured (Fig. 5a,b,c).  There was also no difference between the 
drug or vehicle groups for the drop test (Fig. 5d).  Previous data collected from mice with a 
C57Bl/6J background indicated that the Rai1+/- mice have a significantly larger landing splay 
(S. Girirajan thesis, 2008), but the C57Bl/6J:FVB/NJ mixed background appears to mute this 
phenotype. 
 
 
 29 
 
 
Figure 5. Gating tests and drop test of ampakine and vehicle injected mice. All data reported 
as mean±s.e.m.  
 
 
Next, a hot plate test was performed to determine if the ampakine treatment could correct 
the delayed response to nociceptive pain documented in Rai1+/- mice.  As shown in Fig. 6a, the 
Rai1+/- vehicle treated female stayed a longer time on the hot plate, which is consistent with 
what has been previously found (S. Girirajan’s thesis).  Interestingly, the drug treated female 
mice stayed on the hot plate for about the same amount of time as the WT vehicle treated female, 
indicating that the pain response is improved (Fig. 6a). However, there were no significant 
differences between the groups of male mice (Fig. 6b).  As there were not enough mice to reach 
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any firm conclusions from this study, further study needs to be done to confirm the affect of 
ampakine treatment this phenotype.  
 
 
 
 
 
 
Figure 6. Initial hot plate test of ampakine and vehicle treated Rai1+/- and WT mice. 
Maximum time for each mouse to be on the hot plate was 20 seconds. The data shows females 
and males separately.  
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Feeding Behavior 
Over the course of the 8 week study, the weight of each mouse was recorded weekly and 
the growth curve was observed (Fig. 7a).  Interestingly, drug treated Rai1+/- female gained a 
great deal of weight, while the growth of vehicle treated Rai1+/- female was comparable to WT 
vehicle treated female (Fig. 7a).  On the other hand, the males weighed more than the females, 
and vehicle treated Rai1+/- male mice seemed to gain more weight than WT male (Fig. 6b).  
Additionally, the mice's feeding behaviors were observed to access hyperphagia and its possible 
correlation with growth curves (Fig. 8).  Pre-weighed food was given for 5 days, and the amount 
eaten was recorded.  Two different sets of 5 days were observed.  In order to normalize the 
amount that each mouse consumed, the daily amount consumed was divided by their weights.  It 
was expected that the Rai1+/- vehicle treated mice would consume more food relative to their 
weights.  Interestingly, that was not the case.  There were no differences relative to weight in the 
amount of food consumed between Rai1+/- vehicle female and Rai1+/- drug treated female, and 
no shifts in eating habits were found  (Fig. 7). It is really interesting to see that Rai1+/- drug 
treated female ate relatively similar amount with Rai1+/- vehicle treated and yet still managed to 
maintain similar weight with WT vehicle treated. This suggests that there is some other 
metabolic pathway that is altered in Rai1+/- that is responsible for their weight changes.  Judging 
by these results, the drug does not seem to have any effect on the eating behaviors in these mice.  
It is important to note that vehicle treated and drug treated Rai1+/- females did not start their 
growth curve at equal weights.  Therefore, further study is needed with a greater number of mice 
to confirm these results.  
Overall, the results of this initial study suggest that further study is needed if the hot plate 
test, weight gain test and relative feeding study are to confirm the effects of the drug.  
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Figure 7. Weight of ampakine and vehicle treated Rai1+/- and WT mice. Mice were 
separated by gender and treatment group. Individual mice were plotted. Female group is on top 
and male group is at the bottom.  
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Figure 8. Initial food consumption of ampakine and vehicle treated Rai1+/- and WT mice. 
Daily food intake was measured and divided by their weight of the mouse. The data show 
females and males separately.  
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II. Second batch 
For the second batch, 29 mice were used, of which 16 of them were Rai1+/- mice, and 23 
were WT mice.  Of the 16 Rai1+/- mice, 8 were in the vehicle group while the remaining 8 were 
in the drug treatment group.  For the WT animals, 6 of them received the vehicle, and 7 were 
injected with the drug.  Also, the mice were grouped into two age groups: 7 and 16 weeks.   
This round was conducted by another student in our lab (K. Schmidt, 2010).  
 
Hot plate test.  
As the drug seemed to have an effect on restoring the pain sensitivity of Rai1+/- mice, 
the hot plate test was repeated (K. Schmidt, 2010).  As shown in Fig. 9, Rai1+/- mice can 
tolerate the hot plate a significantly longer amount of time than their WT littermates, regardless 
of gender (p<0.0001, Fig. 9).  When the Rai1+/- mice are treated with ampakines, the pain 
response in the Rai1+/- improves, and they showed a quicker pain response and spent less time 
on the hot plate than Rai1+/- vehicle mice.  However, Rai1+/- drug treated mice spent 
significantly more time on the hot plate than the WT ampakine treated mice (p<0.0001, p= 
0.0209, Fig. 9). 
  With regard to the hot plate test, a few difficulties need to be mentioned. First, the time 
recording was done in a subjective manner.  It is the observer’s call to stop the watch when the 
mice seem to have a pain response.  As mice tend to rear in response to pain, the data might not 
be the most accurate account of pain sensitivity. Further study needs to be done with more 
objective testing methods, for example, with an automated time recorder, in order to confirm 
these results.  
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Source from Kristie Schmidt’s thesis, 2010 
Figure 9.  Hot plate test of ampakine and vehicle treated Rai1+/- and WT mice.  Maximum 
time for each mouse to be on the hot plate was 20 seconds.  All data reported as mean ± s.e.m. 
*P< 0.05, ***P< 0.0001. 
 
Behavioral Testing. 
Behavioral responses were evaluated in an operant test in which the mice learn to push a 
lever to receive food.  It was predicted that if the ampakine treatment was decreasing the amount 
of food intake, that the Rai1+/- mice would be less likely to press the bar for pellets than their 
vehicle treated Rai1+/- siblings.  Using a generalized linear model with poisson distribution, 
statistical analysis was performed to see if there was any differences in behavior between the 
groups.  A trend suggests that drug treated mice, regardless of genotype, pushed the bar more 
frequently to receive food pellets.  Further, when looking at treated mice specifically, the drug 
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treated mice both pressed levers significantly more often than vehicle treated mice, regardless of 
genotype (p<0.0001, Fig. 10). This suggests that the drug has some effect on their behavior, as 
only the drug treated group showed a different response regardless of the genotype.  Based on 
this data, different interpretations can be made.  It could be that the drug is making the mice 
more hyper or possibly “smarter.”  Note that there were 3 training sessions in which the mice 
learned that pressing the lever gives them food, and those data were only recorded during the 4th 
and the longest session.   As the data shows a significant difference in the case of the drug treated 
group, it is possible that the treatment enhanced the treated mice' learning ability. It is important 
to note that the food eaten was not recorded and this is something that should be evaluated in the 
future. 
 
 
 
Figure 10. Operant test of ampakine and vehicle treated Rai1+/- and WT mice.  Operant 
data evaluated as bar presses/60 min, completed after 2 training periods.  Statistics were done 
using a generalized linear model with tests of fixed effects, p-value  <0.0001. 
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Growth assessment and feeding behavior 
For the second batch, the weights were measured every day over a 2-week time period.  
The mice were separated into age and gender groups.  Interestingly, the mice did not show 
significant changes in weight.  There are few things to note, however.  At day 1 of ampakine 
treatment, the 7 week old female Rai1+/- and WT drug treated mice had significantly different 
weights (p = 0.0211, Fig. 11).  The 7 week old female Rai1+/- and WT vehicle treated mice (p = 
0.0056, Fig. 11) and vehicle treated mice (p = 0.0056, Fig. 11) had  significantly different 
weights.  At day 1 of ampakine treatment, the 16 week old female Rai1+/- and WT drug treated 
mice had significantly different weights (p = 0.0074, Fig. 11).  Male Rai1+/- and WT mice had 
no significant differences in weight at 7 or 16 weeks of age (Fig. 11).  It is interesting to note that 
the trends for the vehicle and drug treated Rai1+/- mice in the 16 week old age group were the 
same.  However, the data as a whole indicate that all of the mice in each of the dosage groups 
stayed at approximately the same weight throughout the study. Therefore, any effect the drug 
may have had on the growth curve is hard to conclude from this study.   
Next, food intake was measured every day over a 2-week period.  Each day, the amount 
of food the mice ate was measured and data was recorded as amount eaten divided by the 
weights (Fig. 12).  Over the course of the 2-week period, when mice groups were compared, 
there was a significant difference in the Rai1+/- Drug and Rai1+/- vehicle treated (p=0.0006). 
However, there was no significant difference between Rai1+/- Drug and WT drug treated 
(p=0.3254). The significant difference seen in Rai1+/- drug mice can be due to the food 
crumbling seen in the drug treated Rai1+/- females. This behavior might have gave a false 
positive result as measurement of food cannot be accurate for it is difficult to account for the 
extra food seen at the bottom of the cages. Also, between the male groups, there were no 
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significant difference in any of the groups (p= 0.6893).  
Overall, restoration of pain sensitivity is observed consistently in both the first and 
second batch (Fig. 6, Fig. 9).   
 
 
Figure 11. Weight of ampakine and vehicle treated Rai1+/- and WT mice. Weights of 7 and 
16 week old ampakine and vehicle treated female mice on top and male mice oat the bottom.  
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Figure 12. Food intake study. Age groups were pooled together as no significant differences 
were found between the groups. ***p=0.0006 
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Expression Studies in ampakine treated Rai1+/- mice  
After completion of the 2-week treatment period, all 29 mice were euthanized and their 
brain tissue was collected.  For the RNA extraction, the brain without hypothalamus was 
homogenized.  The mRNA expression level of Bdnf was evaluated to confirm that ampakine 
treatment increases Bdnf level. 
 The data show that ampakine treatment caused a subtle increase in Bdnf expression in 
WT mice as well, as there was ~1.2 fold increase in expression in the WT treated group.  Also, 
the Bdnf level was increased (to ~80%) when compared to Rai1+/- controls, which showed about 
50% expression compared to the WT control, a result that is consistent with previous findings 
(B. Burns, 2009) (Fig. 13).  Interestingly, the Bdnf level in vehicle treated mice increased as well 
and there is no significant differences in the level of Bdnf between Rai1+/- drug and vehicle 
treated mice (p= 0.5523) (Fig. 13).  This could potentially be due to the HPCD diluent contained 
in the vehicle, or could possibly be a result of handling.  Further investigation needs to be done 
without HPCD to narrow down the cause of the increased Bdnf expression shown in vehicle 
treated mice.  
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Figure 13. mRNA Bdnf expression studies.  Results of expression analysis of Bdnf in brain 
tissues without hypothalamus is shown. Data are reported with mean ± s.e.m. n$3.  
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III. Third batch  
For the last batch, 12 mice were used.  All of these mice were males, of which 6 were 
drug treated and the other 6 were vehicle. The treatment was continued for 5 days by IP injecting 
either the drug or vehicle solution. Same drug was used with same concentration and dosage of 
administration.  
 
Tail flick test.  
The tail flick test was performed on the 5th day of treatment.  This test gives automated 
results, thereby yielding more objective data.   However, this test is still difficult to perform, as 
the mouse's body must be held by hand while the tail is exposed in the apparatus.  As stated 
previously, these mixed background mice are very jumpy and hyper, resulting in a number of 
handling difficulties because the mice kept moving and it was hard to get them still enough to 
perform the test. 
 
Figure 14. Tail flick test. Tail flick response was observed between the groups. No significant 
differences were found between any groups. p= 0.3986 
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Discussion 
 
 
For this study, the effect of an ampakine drug, CX1837on Rai1+/- mice was evaluated.  
First, many physical assessment were made to ensure that the drug did not cause any negative 
side effect or act as a sedative.  These tests included sound orienting, pupil constriction/dilation, 
whisker response, eye blink, ear twitch, postural reflex and response to being picked up by the 
tail.  All mice showed normal responses regardless of genotype or treatment group, suggesting 
that the drug does not have any negative effects on neurological functioning. This assured that 
further investigation of this drug was appropriate.  However, two of the vehicle treated mice had 
unexpected death/sickness, which points to a potential confounding effect from the HPCD, 
which should be removed in the case of future studies.   
There are a few things to highlight from this study.  First, interesting data was observed 
in the hot plate test.  However, the tail flick test was not successful in capturing changes in the 
pain response phenotype.  I believe this is largely due to the strain of mice being used, as this 
mixed background FVB/NJ X C57Bl/6J mouse is not an optimal model for assessment of these 
neurological phenotypes because they are difficult to handle.  Evaluation of the pain response 
has great potential for designing treatments to help with the self-injurious behaviors (i.e. head 
banging, skin picking) seen with SMS as well as other neurological disorders.   
Another effect of the drug seemed to be found in the operant conditioning test.  It is very 
interesting to see that the drug has a significant effect on both WT and Rai1+/- mice.  This 
makes me wonder if the dosage we used was too high, since the WT drug treated mice showed 
the effects as well.  Different drug dosages can be used to assess this effect to further investigate 
if this result is a positive or negative attribute related to drug administration.  
Growth assessment along with the feeding study is another test to be carefully 
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considered.  While the initial suggested that ampakine treatment has an effect on weight gain and 
provides a potential solution for obesity, as female Rai1+/- treated mice did not gain as much 
weight as the vehicle treated mice, there were no significant differences found between the 
treatment and vehicle groups in the second batch.  However, it is important to note that the 
second batch study was only performed for a 2 week period, while the initial study, lasted 8 
weeks.  Unlike changes in neurological or behavioral phenotypes that can be observed within 
short timespan, 2 weeks might not have been enough time to observe weight or growth 
differences, and this result suggests that further investigation needs to be done, with prolonged 
treatment, to see the growth curve accurately.  
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Chapter 4. Effect of ampakine treatment on Bdnf and whole brain global gene 
expression    
 
Introduction 
 
Bioinformatic analyses suggest that RAI1 is likely to play a role as a transcriptional 
regulator; however, its cellular and developmental role is still unclear [15,17]. It has been 
reported that RAI1 shares stretches of sequence with >50%  identity to the transcriptional 
cofactor TCF20, also known as SPBP [18].  TCF20 also shares >90% of similarity with genomic 
structure with RAI1[15].  The RAI1 protein contains two putative bipartite nuclear localization 
signals (NLSs), polyglutamine and polyserine tracts, and a PHD/zinc finger domain at the C-
terminus [14,15]. RAI1 mRNA is ubiquitously expressed throughout the tissues, and relative to 
the other tissues, the heart and brain tissues have stronger expression by two- and threefold, 
respectively [14]. The alteration in dosage of RAI1 is likely to cause alterations in the expression 
of different genes downstream. Thus, when RAI1 is haploinsufficient, BDNF, CLOCK, 
CMKLR1, and many other genes are altered. Also, two other studies have suggested that RAI1 is 
likely to be a transcriptional regulator as well [15,18]. 
BDNF mRNA and protein expression is found throughout the brain with the highest 
expression in the neurons of hippocampus [58,59,60].  Previously, another student in our lab 
(B.M. Burns, 2009) has performed microarray analysis on hypothalami and showed reduced in 
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Bdnf expression in Rai1+/- mice among many genes. Q-RT-PCR analysis of hypothalamic tissue 
confirmed that the Bdnf level was downregulated by ~2.5 fold in Rai1+/- mice compared to WT 
controls [30].  
In this chapter, two questions were proposed. First, re-evaluation of Bdnf expression in 
the whole brain of the mice after the drug treatment (without HPCD) was conducted to see if 
data are consistent with previous findings (Chap. 3).  Next, in order to evaluate other genes that 
are altered due to the CX1837 ampakine drug (restoration of phenotypes as seen in Chap. 3), the 
whole brain global gene expression was evaluated for each mouse and microarray analysis was 
used to compare between Rai1+/- drug vs Rai1+/- vehicle, as well as between WT drug vs WT 
vehicle mice.  
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Materials and Methods 
 
Mouse models, breeding, and maintenance. Mice evaluated in this study were C57Bl/6J 
Rai1+/- animals bred from stock received from Jackson Laboratories (stock #005981).  Due to 
poor in-house breeding of this line, the mice were outcrossed to FVB/N to improve number of 
offspring obtained. When the mice were being bred or in feeding studies, they were given access 
to a higher fat (9%) Lab Diet 5P06 Prolab RMH 2000 diet and water. An automatic 12-hour 
light/dark cycle was provided at all times along with constant temperature (21C) and humidity 
(40%). The overall phenotype of these mice is muted in this mixed background, but the FVB/N x 
C57Bl/6J Rai1+/- animals are overweight and have craniofacial anomalies similar to the B6 
congenic strain originally evaluated.  
 
Ampakine treatment. Data from the previous study suggested 2-hydroxypropyl-#-cyclodextrin 
(HPCD) powder was suggested not to be an optimal vehicle. Thus HPCD was removed from this 
study. An equal mixture of water and 0.9% injectable saline was prepared, and ampakine 
CX1837 (Cortex Pharmaceuticals) was added to half of the volume to a concentration of 0.25 
mg/mL while the remaining half of the saline solution was used as vehicle.  The solution 
containing ampakine CX1837 was then submerged in a sonicator heated to 37C and then 
frequently vortexed to aid solubilization.  The resulting solution is a clear viscous liquid stored in 
4C.   
 
Ampakine injection. Each mouse was weighed weekly and given 1 mg/kg BID of a 0.25mg/mL 
solution of ampakine CX1837 twice daily (10:00 a.m. and 5:00 p.m.).  Vehicle solution was used 
at the same volume for dose of 1 mg/kg.  Before the solution was used, it was mixed well to 
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dissolve any precipitation formed.  The volume of drug was altered once a week to account for 
weight fluctuations in the mice.  The mice were anesthesized with isofluorane prior to 
intraperitoneal (IP) injection.  Each mouse received the dose in the same order every day.  The 
four treatment groups included wild type, WT vehicle treated, WT drug treated, Rai1+/- vehicle 
treated, and Rai1+/- drug treated. 
 
RNA isolation. RNA was isolated using the Trizol reagent/chloroform method.  The quality of 
isolated RNA was assessed by using a 260/280 and 230/260 absorbency ratio, and the 
concentration was obtained using Nanodrop.  
 
Real-time quantitative PCR.  cDNA synthesis was performed using 4-5 µg of RNA, Invitrogen 
Superscript 2 reverse transcriptase and random primers according to the manufacturer’s 
instruction. To detect gene expression, for Bdnf, an ABI TaqMan probe for mouse mRNA 
expression was used. All samples were analyzed in triplicate in a 10 µL reaction on an ABI 
Prism 7500 Fast System with Gapdh as an endogenous control.  
 
Microarray.  Microarray hybridization was performed in the NARF DNA Microarray Core 
using an Illumina MouseRef-8 v2.0 expression beadchip.  The array was read using an Illumina 
BeadArray Reader and analyzed by Illunima’s GenomeStudio software.  
 
Microarray data Analysis.  Using the Illumina GenomeStudio Software, differential analysis 
was performed between the Rai1+/- drug and and WT drug vs vehicle. Data were normalized 
using the quantile method.  Differential P-values were determined using the Illumina custom 
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analysis.  The software was also used to calculate a false discovery rate (FDR) and to adjust p-
values accordingly. Genes with fold changes were evaluated and top candidate genes were found 
for further analysis. 
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Results 
Bdnf gene expression study in ampakine-treated Rai1+/- mice: For the third round of 
ampakine study with a total of 12 mice, the treatment was continued for 5 days by IP injection of 
either the drug or vehicle solution.  All mice in this study were males of the same age.  Among 
the 12 mice, 6 were Rai1+/- and 6 were WT mice.  On the 6th day, before the next injection time, 
all 12 mice were euthanized and their whole brain tissues were collected.  For the RNA 
extraction, the whole brain tissue was homogenized and 1 mL was taken.  The mRNA expression 
level of Bdnf was evaluated to confirm what we had previously found.  It is important to note 
that the vehicle solution in this study was just the mixture of water and saline without HPCD 
powder, to avoid any of the potential negative effects of HPCD.  Ampakine 1837 was only 
dissolved in water and saline as well.   
Fig. 12 shows the results of the Bdnf expression studies via qRT-PCR in Rai1+/- and WT 
drug and vehicle treated mice.  First, both Rai1+/- drug and vehicle treated mice showed an 
elevation in Bdnf level (~up to 80%), and there was no significant difference in levels between 
the drug and vehicle treated Rai1+/- mice (p=0.5523) which is consistent with the previous 
finding (Chap. 3).  However, the Bdnf level was significantly higher in Rai1+/- drug mice 
(p=0.0151), as well as Rai1+/- vehicle (p=0.0281) mice when compared to the Rai1+/- control 
mice.  The control mice are the ones that received neither vehicle nor drug injections. Also, there 
was no significant difference between WT vehicle and either Rai1+/- drug mice (p=0.0536) or 
Rai1+/- vehicle mice (p=0.1564).  One thing that differed in the results of this study was that 
WT drug treated mice seemed to be unaffected in terms of Bdnf expression, consistent with other 
published reports of ampakine treatment and Bdnf expression.  Overall, there were no significant 
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differences between any of the four groups (WT vehicle, WT drug, Rai1+/- drug, Rai1+/- 
vehicle) (p=0.1044) with regard to expression of Bdnf.  Therefore, this study suggests that HPCD 
is not likely to be responsible for the elevation of Bdnf level seen in both Rai1+/- vehicle and 
drug treated mice compared to Rai1+/- control mice. 
 
Figure 15. mRNA Bdnf expression studies in whole brain.  Results of qRT-PCR expression 
analysis of Bdnf in whole brain tissues is shown.  *p "0.05. Data are reported with mean ± s.e.m. 
n=3, each sample run in triplicate.   
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Microarray analysis: The collected RNA from these whole brain samples were also sent out for 
microarray analysis as described in Materials and Methods.  Using the Illumina GenomeStudio 
Software, two different comparison analyses were made.  1) Rai1+/- drug vs. Rai1+/-vehicle 
treated mice and 2) WT drug vs WT vehicle mice, to examine the effects of the drug on the 
alteration of gene expression.  Based on this analysis, the top 5 upregulated and downregulated 
genes were found by comparing the drug and vehicle groups, with the results listed in Table 1.  
Table 1 lists the most affected genes in decreasing order of alteration.  
 First, the top 5 genes that were found to be upregulated due to drug administration in 
Rai+/- drug mice are as follows: Olfr1346, Wrnip1, Bhlhb4, Olfr661, and Tnfrsf13c (Table 1a).  
The top 5 genes that were found to be higher in Rai1+/- drug treated mice compared to Rai1+/- 
vehicle are Nfe2, Olfr986, Mtmr7, Cyp26b1, and prl.  
 When WT drug and WT vehicle groups were compared, the top five genes that were 
upregulated due to drug administration include V1rc21, Evx2, Olfr854, Gbx1, and Trim14.  
Likewise, the top five downregulated genes are Cpa5, Flt3, Vmn2r28, Sec1, and Stxbp6.  These 
top regulated genes include genes involved in the function of DNA binding, genes involved in 
methyl binding, ATP regulation, transcription regulation, hormones, and olfactory regulation.  
In order to understand the possible causes of the pain phenotypes seen from earlier 
ampakine studies (Chap. 3), what was most interesting to look at was the regulation of any pain 
related genes.  In order to help understand the pain related phenotype we saw with the drug 
administration, any significant changes in pain related genes were identified within these data.  
This analysis revealed two genes of interest (Table 2), as described below.  
 Oncostatin M (Osm) showed a 2.8 fold increase in Rai1+/- drug treated compared to 
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Rai1+/- vehicle treated mice.  Oncostatin M is a member of the interleukin-6 (IK-6) family of 
cytokines [78].  These cytokines play important roles in hematopoiesis, inflammation, heart 
development, and neurogenesis [78].  Osm-deficient mice displayed significantly reduced 
noxious responses in models of acute thermal, mechanical, chemical, and visceral pain [78].  It 
was noted that Osm-/- mice did not exhibit any impairment of motor coordination, yet they 
showed to have significant reduction in response to various stimuli including mechanical and 
thermal stimuli [78].  In addition, there was a decrease of a subset of nociceptive DRG neurons 
in adult Osm-/- mice [78]. Increased levels of Osm in Rai1+/- drug treated mice is interesting to 
observe as Rai1+/- drug treated mice have elevated pain response and Osm is responsible for 
pain sensitivities. Further study needs to be done on this gene in Rai1+/- mice and its possible 
regulation by Bdnf and/or Rai1.  
 Another gene of interest was the glutamate (NMDA) receptor, ionotropic, NMDA2D 
(epsilon 4) (Grin2d), which showed a 0.8 fold increase in Rai1+/- drug treated mice when 
compared to Rai1+/- vehicle treated mice.  It was not surprising to see up-regulation of this gene 
in the drug treated mice, as the ampakine drug is known for binding to its AMPA receptor and 
causing an increase in glutamate.  NMDAR (receptor for NMADR) has a crucial function in 
brain development, plasticity and survival [78,79].  Deregulation of these receptors can 
contribute to a variety of neurological and neurodegenerative disorders [81,82]. This gene also 
modulates the frequency, rate or extent of the sensory perception of pain, and the series of events 
required for an organism to receive a painful stimulus, convert it to a molecular signal, and 
recognize and characterize the signal.  
These two genes need to be given special attention in Rai1+/- animals that are both 
untreated with ampakine and untreated in order to determine if this is consistently altered gene in 
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SMS.   Quantitative RT-PCR expression analysis need to be done to confirm the alterations of 
these genes.  Overall, it is important to note that this analysis was done in a very basic manner, 
and further in-depth analysis is needed. Specifically, researchers should looks further down the 
list of top regulated genes (i.e. the top ten or more) to see if there are any other genes of interest. 
These genes should be studied in greater depth to learn more about their functions and roles.  
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Table 1. Top disregulated genes found between ampakine and vehicle treated Rai1+/- mice 
by fold difference. a. Top upregulated genes. b. Top downregulated genes.   
a. 
Gene Symbol Fold change Gene name Functions 
Nfe2 9.6 
 
nuclear factor, 
erythroid derived 2 
Chr15; DNA binding 
Olfr986 7.2 
 
olfactory receptor 986 Chr9; olfactory receptor 
activity 
Mtmr7 5.8 
 
myotubularin related 
protein 7 
Chr8; hydrolase activity 
Cyp26b1 5.8 
 
cytochrome P450, 
family 26, subfamily 
b, polypeptide 1 
Chr6; metal ion binding 
Prl  5.5 
 
prolactin Chr 13; hormone activity 
 
b. 
Gene Symbol Fold change Gene name Functions 
Olfr1346 
 
8.4 
 
olfactory receptor 
1346 
Chr15; olfactory receptor activity 
Wrnip1 
 
6.7 
 
Werner helicase 
interacting protein 
1 
Chr13; ATP binding 
Bhlhb4 
 
5.6 
 
basic helix-loop-
helix family, 
member e23 
Chr 2; Transcription regulated 
activity 
Olfr661 
 
5.1 
 
olfactory receptor 
661 
Chr7; Olfactory receptor activity 
Tnfrsf13c 4.9 
 
tumor necrosis 
factor receptor 
superfamily, 
member 13c 
Chr 15; Receptor activity 
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Table 2. Top disregulated genes found between ampakine and vehicle treated WT mice by  
fold difference. a. Top upregulated genes. b. Top downregulated genes.  
a. 
Gene Symbol Fold change Gene name Functions 
V1rc21 8.3 
 
vomeronasal 1 
receptor 4 
Chr6; pheromone binding 
Evx2 5.9 
 
even skipped 
homeotic gene 2 
homolog 
Chr2; DNA binding 
Olfr854 5.6 
 
olfactory receptor 854 Chr9; olfactory receptor 
activity 
Gbx1 5.2 
 
gastrulation brain 
homeobox 1 
Chr5; DNA binding 
Trim 14 5.2 
 
tripartite motif-
containing 14 
Chr 4; Metal ion binding 
 
b. 
Gene Symbol Fold change Gene name Functions 
Cpa5 
 
7.3 
 
carboxypeptidase A5 Chr6; carboxypeptidase 
activity 
Flt3 
 
5.5 
 
FMS-like tyrosine 
kinase 3 
Chr5; ATP binding 
Vmn2r28 
 
5.1 
 
vomeronasal 2, 
receptor 28 
Chr 7; G-protein coupled 
receptor 
Sec1 
 
4.4 
 
secretory blood group 
1 
Chr 7; Fucosyltransferase 
activity 
Stxbp6 
 
4.3 
 
syntaxin binding 
protein 6 
Chr 12;Molecular function 
 
Table 3. Pain related genes and their fold changes. Pain related genes were of particular 
interest, and the top two upregulated pain-related genes in Rai1+/- drug were noted. 
 
Gene Symbol Fold change Gene name  Process & function 
Osm 
 
2.3 
 
oncostatin M Chr11; response to pain  
Grin2d 
 
0.8 
 
glutamate receptor, 
ionotropic, 
NMDA2D (epsilon 4) 
Chr7; modulates the 
frequency, rate or extent 
of the sensory perception 
of pain 
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Discussions 
In this study, we re-evalulated Bdnf expression in mice that were given CX1837 drug and 
vehicle treatment.  This time, HPCD was removed from both the drug and vehicle solutions, due 
to the negative effects associated with its use, as noted in the previous study.  HPCD was 
originally used because the drug powder is not easily soluble, and HPCD aids solubilization and 
thus, the delivery of the drug.  In this study, the drug was dissolved for a longer period of time, 
until it formed clear solution.  Interestingly, when we evaluated Bdnf expression in these sets of 
mice, the Bdnf level was still found to be elevated in the vehicle treated mice (Fig 2).  This 
suggests that HPCD is not the reason for the increase of Bdnf expression in vehicle treated mice, 
and that something else might be going on.  These results lead me to ask: 1) Did the Bdnf level 
increase simply because of handling the mice twice daily? or 2) Did it increase because of the 
sedation of the mice with isofluorine prior to vehicle injection?  
It has been reported that “early handling” of rats increases Bdnf expression in the rat 
hippocampus [80]. It is also known that physical exercise is associated with an increased in Bdnf 
mRNA [81]. In one study, it was found that there was a significant, positive correlation between 
the mean distance run per night and Bdnf mRNA in the hippocampus [81].  Also, whisker 
stimulation and light stimulation increases Bdnf mRNA expression in the somatosensory barrel 
cortex and visual cortex, respectively [82,83].    
In order to clarify the question for possible cause of increased in Bdnf level in vehicle 
treated Rai1+/-, it will be interesting to evaluate mice with just handling itself without injecting. 
This will help us better understand any possible associations between Bdnf expression and 
animal handling.  Thus, in order to clarify the possible cause of an increase in Bdnf level in 
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vehicle treated Rai1+/- mice, it would be interesting to evaluate Bdnf levels in mice that are 
handled, but not given injections of any kind, and utilize as controls mice that are not handled at 
all.  
 Next, global gene expression analysis was performed on whole brains from mice in this 
study by microarray using an illumina MouseRef-8 v2.0 expression beadchip.  The top candidate 
genes were found between drug and vehicle treated mice among Rai1+/- and WT.  The top 5 
upreulated genes due to drug administration among Rai1+/- mice include Nfe2, Olfr986, Mtmr7, 
and Cyp26b1; however, most interesting to look at were alterations in pain related genes.  Two 
candidate genes were identified.  Interestingly, Osm-/- mice have been reported to exhibit a 
significant reduction in pain related responses. This has a direct relationship with the restoration 
to the pain response seen in the Rai1+/- treated mice. Osm is potentially one of the genes 
responsible for this observed phenotype. Thus, this gene will be the top priority gene for further 
study, as it is likely to be involved in the pain related responses we have observed in drug treated 
mice.   Further analysis is also needed of the other top altered genes to determine how ampakine 
drug treatment restores phenotypes, connects with SMS phenotypes, and how this drug can be 
ultimately used as a potential treatment for SMS patients. 
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Chapter 5. Discussion 
 
After completion of this project, we discovered more about the function of RAI1 and its 
regulation of BDNF and how it connects to SMS phenotypes.  First, we confirmed that RAI1 
regulates BDNF within an intronic region, and this sequence was further narrowed down.  This 
finding is consistent with what was found before using ChIP-chip assay and microarray analysis 
of Rai1+/- mice hypothalami.  Next, in order to evaluate the role of Bdnf, ampakine drug was 
utilized in the Rai1+/- mouse model.  A mouse model is particularly useful when studying a 
specific gene.  Many physical, neurological, and behavioral tests were performed in mice.  
Significant results were obtained in the hot plate test and operant conditioning test.  The hot plate 
data suggest a potential role of BDNF in the SMS phenotype regarding decreased in pain 
sensitivities.  However, because the tail flick test did not capture the pain phenotype observed in 
the hot plate test, this aspect of the phenotype still needs to be re-investigated with more 
sophisticated tests.   
Unexpected results were found in the gene expression studies via qPCR, which showed 
an elevation of the Bdnf level in vehicle-treated mice.  This is inconsistent with what other 
studies have shown.  For example, in the Huntington disease mouse model, ampakine treated 
mice had higher Bdnf levels than those given vehicle in western blot analysis [76]. Also, the 
study showed that ampakine did not alter Bdnf levels in WT mice [76].  However, western blot is 
not an accurate quantitative measurement.  Also, it could be due to use of a different type of 
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ampakine, as this study used CX929 at a different concentration than our study.   
From the data shown here study, it is important to note that any significant findings  can 
be due to other factors or genes that were caused by drug administration.  Also, after completion 
of this study, one has to consider other means by which the expression level of Bdnf might 
increase.  Could daily handling of mice alter the Bdnf level?  Does administration of anesthetic 
alter Bdnf?  More evaluations and further study of possible variables (i.e. drug concentration, 
animal handling, etc.) need to be done to discover more about this ampakine drug and its effects.  
Lastly, Bdnf levels were compared between the Rai1+/- drug and vehicle treated mice 
without HPCD diluent. Interestingly, the vehicle mice still had elevated Bdnf level and there was 
no differences between the Rai1+/- drug and vehicle treated with regard to expression of Bdnf.  
Also, microarray analysis was performed on whole brain to evaluate the global expression 
analysis and top candidate genes that were altered due to drug administration were discovered. 
The top 5 genes that were altered due to administration were identified to be Olfr1346, Wrnip1, 
Bhlhb4, Olfr661, and Tnfrsf13c. Also, considering pain restoration phenotype found due to drug 
administration, any pain related genes were evaluated. Two candidate genes Osm, and Grin2d 
were identified. Increased level of Osm in Rai1+/- drug treated mice is interesting to observe as 
Rai1+/- drug treated mice have elevated response and Osm is responsible for pain sensitivities. 
Overall, these studies opened up many other areas to explore regarding Bdnf levels, 
mouse behavior, and ampakine drugs. Therefore, I suggest future directions for each aim below.  
 
Future directions for Aim 1.  
We have confirmed that RAI1 has a direct binding sequence in the BDNF intronic region, 
and we have further narrowed down its sequence to ~800 bp.  For the future, further narrowing 
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down within this region would be a logical follow-up.  Starting with BDNF shortLuc., even 
shorter pieces can be created and the relative luciferase activities examined until there is no more 
alteration in luciferase activity observed; thus, identifying the exact consensus binding sequence 
for RAI1.  I think the remaining RAI1 binding sequence found in the ChIP-ChIP should be 
removed last, as it will be very informative to know that ChIP-ChIP analysis is actually showing 
the accurate binding peak.  From this suggested study, we can ultimately find a consensus 
binding sequence.  
Next, it will be also interesting to take the sequence that was removed from the original 
BDNFLuc., thereby creating another short form of BDNF to see if RAI1 also regulates BDNF 
expression via this region.  It is still possible to see some regulation, as potential repression or 
additional enhancer regions can lie within the sequence.  
It is also important to study the pathway downstream from BDNF, as this will further 
narrow down the specific role of BDNF, as many different roles of BDNF have been found, as 
previously stated.  
 
Future directions for Aim 2.  
Because the tail flick test did not capture the pain phenotype previously observed in the 
hot plate test, this aspect of the phenotype still needs to be re-investigated.  More sophisticated 
tests need to be done to better assess the pain sensitivity experienced by the ampakine treated 
mice.  Options include incision prior to ampakine injection and/or lactic acid injection [84,85].  
 Another possibility that is more costly but potentially a better option in terms of long 
term testing is to obtain a different strain of mice that are known for having calmer behavioral 
characteristics.  If the mice are calmer and easier to handle, not only can pain sensitivity be re-
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evaluated, but other tests could be added that might capture other phenotypes not seen in this 
study.  Also, the consequences of drug administration can be more easily observed.   
Furthermore, another study could be done by altering the ampakine dosage or by using 
different types of ampakine, such as CX1739.  For this study described here, the maximum 
suggested dosage was used.  Injecting a smaller amount of the drug would allow the minimum 
dosage needed for effect to be observed, which would be useful in evaluating ampakines as a 
potential treatment for SMS and other syndromes with reduced pain sensitivity.  It would be 
helpful to know the minimum dosage for oral administration.  Also, examining different dosages 
can potentially help us find an even better dosage that works more effectively in these mice.  
 
Future directions for Aim 3. 
 Using a microarray to evaluate expression of genes in the whole brain of drug treated and 
vehicle treated WT and Rai1+/- mice, we found top candidate gens that are altered due to drug 
administration.  Also, pain related genes were identified.  Direct follow up from this study would 
be to take these candidate genes and perform Q-PCR to confirm the true alterations in the 
expression.  Furthermore, as we now have microarray data from both the whole brain and 
hypothalamus (B.M. Burns, 2009) of the mice, we can compare these data and analyze to see if 
there are any genes that are commonly and differently expressed within these tissues.   
At last, use of a pure strain for any additional studies to assess drug effects would 
minimize background noise in the microarray data.  Further, specific regions of the brain, such as 
hippocampus, which is the tissue that Bdnf is most highly expressed, can be used.  
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